CC
Caxton Corporation Portfolio holdings
AUM
$22.9M
1-Year Est. Return
106.19%
1 Year Est. Return
+106.19%
AUM
$22.9M
AUM Growth
+$13M
(+132%)
Holding
12
Top Buys
| 1 | +$3.6M | |
| 2 | +$830K | |
| 3 | +$35.1K | |
| 4 |
SAB Biotherapeutics
SABS
|
+$22K |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$9.56K |
Sector Composition
| 1 | Healthcare | 87.24% |
| 2 | Financials | 1.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rezolute
RZLT
$824M
| $18.7M | 81.7% |
1,986,818
+382,832
|
|
||
2
SPDR Gold Trust
GLD
$141B
| $2.59M | 11.33% |
7,286
+2,334
|
|
||
|
3
Berkshire Hathaway Class B
BRK.B
$1.09T
| $327K | 1.43% |
651
+19
|
|
||
4
MindMed
MNMD
$1.17B
| $318K | 1.39% |
27,011
-7,062
|
|
||
5
Enliven Therapeutics
ELVN
$1.22B
| $268K | 1.17% |
13,097
|
|
||
6
Compass Therapeutics
CMPX
$928M
| $187K | 0.82% |
53,503
+10,038
|
|
||
|
BCAX
7
Bicara Therapeutics
BCAX
$940M
| $173K | 0.76% |
10,941
|
|
||
8
Kyverna Therapeutics
KYTX
$287M
| $138K | 0.6% |
22,981
|
|
||
9
Lexeo Therapeutics
LXEO
$607M
| $115K | 0.5% |
17,332
|
|
||
10
Inhibikase Therapeutics
IKT
$171M
| $26.6K | 0.12% |
16,393
|
|
||
|
11
SAB Biotherapeutics
SABS
$173M
| $22K | 0.1% |
+10,935
|
|
||
12
Context Therapeutics
CNTX
$97.4M
| $17.8K | 0.08% |
18,403
|
|